<div id="readability-page-1"><p>Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report)'s share price traded down 5.1% during trading on Friday . The stock traded as low as $1.79 and last traded at $1.7850. 1,827,647 shares were traded  during mid-day trading, a decline of 80% from the average session volume of 9,124,740 shares. The stock had previously closed at $1.88.</p><h2>Analysts Set New Price Targets</h2><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>PACB has been the subject of several recent analyst reports. Stephens lifted their price target on Pacific Biosciences of California from $1.80 to $2.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, November 10th. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Pacific Biosciences of California in a research report on Wednesday, October 8th. Barclays upped their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Monday, December 15th. Finally, Piper Sandler lifted their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 11th. Three investment analysts have rated the stock with a Buy rating, three have issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, Pacific Biosciences of California presently has an average rating of &#34;Hold&#34; and an average price target of $2.08.</p><p><b>View Our Latest Analysis on PACB</b></p><h2>Pacific Biosciences of California Stock Down 5.1%</h2><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>The firm's 50-day moving average price is $2.04 and its 200-day moving average price is $1.59. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40. The company has a market cap of $538.91 million, a price-to-earnings ratio of -0.81 and a beta of 2.32. </p><p>Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings results on Wednesday, March 29th. The biotechnology company reported ($0.23) earnings per share for the quarter. Pacific Biosciences of California had a negative return on equity of 101.49% and a negative net margin of 325.02%.The business had revenue of $3.34 million for the quarter.  Sell-side analysts forecast that  Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year. </p><h2>Institutional Trading of Pacific Biosciences of California</h2><p>A number of hedge funds have recently made changes to their positions in the company. Edmond DE Rothschild Holding S.A. lifted its holdings in  Pacific Biosciences of California by 2.4% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 21,855,180 shares of the biotechnology company's stock worth $25,789,000 after buying an additional 508,700 shares in the last quarter.  Vanguard Group Inc. increased its position in shares of  Pacific Biosciences of California by 2.3% during the third quarter. Vanguard Group Inc. now owns 16,379,972 shares of the biotechnology company's stock worth $20,966,000 after acquiring an additional 362,797 shares during the last quarter.  Geode Capital Management LLC lifted its stake in shares of  Pacific Biosciences of California by 6.4% in the second quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company's stock worth $8,333,000 after acquiring an additional 401,637 shares in the last quarter.  Millennium Management LLC lifted its stake in shares of  Pacific Biosciences of California by 500.9% in the third quarter. Millennium Management LLC now owns 4,916,795 shares of the biotechnology company's stock worth $6,293,000 after acquiring an additional 4,098,555 shares in the last quarter.  Finally, Koss Olinger Consulting LLC boosted its holdings in  Pacific Biosciences of California by 10.0% in the second quarter. Koss Olinger Consulting LLC now owns 3,300,000 shares of the biotechnology company's stock valued at $4,092,000 after purchasing an additional 300,000 shares during the last quarter. </p><h2>About Pacific Biosciences of California</h2> (Get Free Report)<p>Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company's proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.  </p><p>Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Pacific Biosciences of California</li><li>Washington prepares for war</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Nvidia x 1,000,000</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>The McDonald's Secret</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pacific Biosciences of California Right Now?</h2><p>Before you consider Pacific Biosciences of California, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacific Biosciences of California wasn't on the list.</p><p>While Pacific Biosciences of California currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PACB

<p>Pacific Biosciences of California (NASDAQ:PACB) shares fell 5.1% to $1.7850, with trading volume down 80% from the average. Analysts have mixed ratings, with price targets ranging from $1.50 to $2.00. The company, known for its DNA sequencing technology, reported a negative return on equity and net margin. Institutional investors have adjusted their holdings, with some increasing their stakes. The firm's market cap is $538.91 million.</p>

Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.1% - What's Next?